Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EPRX.TO
- Price
- 4.56
- Stock movement up
- +0.12 (2.70%)
- Company name
- Eupraxia Pharmaceuticals Inc
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 162.44M
- Ent value
- 146.46M
- Price/Sales
- 54.53
- Price/Book
- 8.90
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 0.11%
- 1 year return
- 26.67%
- 3 year return
- 42.08%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-18
DIVIDENDS
EPRX.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 54.53 |
| Price to Book | 8.90 |
| EV to Sales | 49.17 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 35.62M |
| EPS (TTM) | -0.75 |
| FCF per share (TTM) | -0.72 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.98M |
| Gross profit (TTM) | 1.33M |
| Operating income (TTM) | -32.97M |
| Net income (TTM) | -26.78M |
| EPS (TTM) | -0.75 |
| EPS (1y forward) | -0.86 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 44.70% |
| Operating margin (TTM) | -1106.75% |
| Profit margin (TTM) | -898.97% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 31.90M |
| Net receivables | 212.41K |
| Total current assets | 33.56M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 867.86K |
| Total assets | 34.17M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 6.38M |
| Total current liabilities | 15.88M |
| Total liabilities | 15.92M |
| Shareholder's equity | 18.25M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -27.62M |
| Capital expenditures (TTM) | 77.89K |
| Free cash flow (TTM) | -25.56M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -146.73% |
| Return on Assets | -78.36% |
| Return on Invested Capital | -108.95% |
| Cash Return on Invested Capital | -103.99% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.55 |
| Daily high | 4.60 |
| Daily low | 4.38 |
| Daily Volume | 11K |
| All-time high | 8.90 |
| 1y analyst estimate | 10.13 |
| Beta | 1.23 |
| EPS (TTM) | -0.75 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 Jun 2025 |
Downside potential
Loading...
Downside potential data
| EPRX.TO | S&P500 | |
| Current price drop from All-time high | -48.76% | -14.12% |
| Highest price drop | -87.48% | -56.47% |
| Date of highest drop | 16 Aug 2022 | 9 Mar 2009 |
| Avg drop from high | -49.09% | -11.07% |
| Avg time to new high | 94 days | 12 days |
| Max time to new high | 549 days | 1805 days |
COMPANY DETAILS
Marketcap
162.44M
Marketcap category
Small-cap
Description
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Employees
29
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging i...
April 24, 2025
The Canadian market has shown resilience, with the TSX rising over 2% recently, even as global markets grapple with tariff uncertainties and economic pressures. In such a climate, investors often look...
April 18, 2025
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
March 22, 2025
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize dru...
March 20, 2025
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company specializing in precision local drug delivery, today announced additional...
February 25, 2025
As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $12 price target Eupraxia is leveraging its DiffuSphere drug delive...
February 22, 2025
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new...
February 18, 2025
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today unveiled new pharmacokinetic ("PK") data from its Phase 2a Eosinop...
November 20, 2024
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize d...
November 14, 2024
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize d...
November 13, 2024
Next page